Shopping Cart
Remove All
Your shopping cart is currently empty
GSK8573
Copy Product Info
😃Good
Catalog No. T15441Cas No. 1693766-04-9
GSK8573 is an inactive control compound for GSK2801, with binding activity to BRD9 (Kd of 1.04 μM).
GSK8573
Copy Product Info😃Good
Purity: 99.97%
Catalog No. T15441Cas No. 1693766-04-9
GSK8573 is an inactive control compound for GSK2801, with binding activity to BRD9 (Kd of 1.04 μM).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | $32 | - | In Stock | |
| 10 mg | $51 | - | In Stock | |
| 25 mg | $96 | - | In Stock | |
| 50 mg | $153 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $30 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.97%
Appearance:Solid
Color:Yellow
Contact us for more batch information
Product Introduction
GSK8573 AI Summary
GSK8573 exhibits selective bioactivity characterized by its binding affinity with various proteins such as BRD9, SMARCA2, and SMARCA4 in human HUT78 cell extract, and with biotinylated C-terminal Avi/His-TEV-fused BRD9 expressed in Escherichia coli. Affinity levels vary with each protein, indicated by Kd values from chemoproteomic competition binding assays and isothermal titration calorimetric (ITC) analysis. Thermal Shift Assays reveal that GSK8573 can both increase and decrease melting temperatures (Delta TM) of different protein domains, indicating complex interactions with protein structures.
In cellular assays, GSK8573 impacts cell viability variably across different cell lines. It shows no significant growth effect in HEK293T and most U2OS cell assays, along with human fibroblasts, but some U2OS and fibroblast assays report a growth rate increase. The compound also demonstrates low bioactivity regarding BAZ2A and BAZ2B targets, with IC50 values over 100,000 nM and Kd values exceeding 10,000 nM, indicating weak or negligible interaction.
Additionally, in Bromodomain panel assays, GSK8573 shows a relative signal of 0.04 with BRD9 and less than -0.05 with BAZ2A. ITC assays report a Kd value of 1040.0 nM with BRD9, suggesting a moderately higher affinity with this target. Overall, GSK8573's bioactivity varies substantially with different proteins and cell types, showing specificity and differential binding affinities..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | GSK8573 is an inactive control compound for GSK2801, with binding activity to BRD9 (Kd of 1.04 μM). |
| Targets&IC50 | BRD9:1.04 μM (Kd) |
| Molecular Weight | 323.39 |
| Formula | C20H21NO3 |
| Cas No. | 1693766-04-9 |
| Smiles | CCCOc1ccn2c(cc(-c3cccc(OC)c3)c2c1)C(C)=O |
| Relative Density. | 1.12 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 22 mg/mL (68.03 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.18 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy GSK8573 | purchase GSK8573 | GSK8573 cost | order GSK8573 | GSK8573 chemical structure | GSK8573 formula | GSK8573 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.